[go: up one dir, main page]

AR076929A1 - Composicion farmaceutica para modular las funciones mediadas por claudina. uso de un derivado de acido graso - Google Patents

Composicion farmaceutica para modular las funciones mediadas por claudina. uso de un derivado de acido graso

Info

Publication number
AR076929A1
AR076929A1 ARP100101835A ARP100101835A AR076929A1 AR 076929 A1 AR076929 A1 AR 076929A1 AR P100101835 A ARP100101835 A AR P100101835A AR P100101835 A ARP100101835 A AR P100101835A AR 076929 A1 AR076929 A1 AR 076929A1
Authority
AR
Argentina
Prior art keywords
fatty acid
acid derivative
pharmaceutical composition
claudine
claudin
Prior art date
Application number
ARP100101835A
Other languages
English (en)
Inventor
Ryuji Ueno
Sachiko Tsukita
Original Assignee
Sucampo Ag
Univ Osaka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo Ag, Univ Osaka filed Critical Sucampo Ag
Publication of AR076929A1 publication Critical patent/AR076929A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de un derivado de ácido graso para la produccion de una composicion farmacéutica para modular una funcion mediada por claudina en un sujeto mamífero. Uso del mismo derivado de ácido graso que el anterior para la produccion de una composicion farmacéutica para tratar una enfermedad dermatologica y aquélla para la modulacion de una expresion de una claudina en un sujeto mamífero. Reivindicacion 15: El uso de acuerdo con la reivindicacion 1, caracterizado porque dicho derivado de ácido graso es ácido (-) -7-[(2R, 4aR, 7aR) -2- (1, 1-difluoropentil)-2-hidroxi-6- oxooctahidrociclopenta [b] piran-5-il] heptanoico o su derivado funcional. Reivindicacion 16: El uso de acuerdo con la reivindicacion 1, caracterizado porque dicha enfermedad dermatologica es una ulcera cutánea o una escara. Reivindicacion 19: El uso de acuerdo con la reivindicacion 17, caracterizado porque dicha funcion mediada por claudina es una funcion de barrera epidérmica.
ARP100101835A 2009-05-27 2010-05-27 Composicion farmaceutica para modular las funciones mediadas por claudina. uso de un derivado de acido graso AR076929A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18146309P 2009-05-27 2009-05-27

Publications (1)

Publication Number Publication Date
AR076929A1 true AR076929A1 (es) 2011-07-20

Family

ID=42352317

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101835A AR076929A1 (es) 2009-05-27 2010-05-27 Composicion farmaceutica para modular las funciones mediadas por claudina. uso de un derivado de acido graso

Country Status (16)

Country Link
US (1) US20100305203A1 (es)
EP (1) EP2435049A1 (es)
JP (1) JP2012528077A (es)
KR (1) KR20120031954A (es)
CN (1) CN102448463A (es)
AR (1) AR076929A1 (es)
AU (1) AU2010253720A1 (es)
BR (1) BRPI1011658A2 (es)
CA (1) CA2761250A1 (es)
IL (1) IL216218A0 (es)
MX (1) MX2011012595A (es)
NZ (1) NZ596555A (es)
RU (1) RU2011153196A (es)
TW (1) TW201102070A (es)
WO (1) WO2010137731A1 (es)
ZA (1) ZA201109532B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
EP4440561A4 (en) * 2021-12-03 2025-12-10 Univ Chicago CLAUDIN INHIBITORS AND THEIR METHODS OF USE

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166174A (en) * 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
JPH01265021A (ja) * 1987-10-29 1989-10-23 Hercon Lab Corp 薬理学的活性物質を含有する組成物を動物組織に制御放出および供給するための物品
CA2030344C (en) * 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
JPH04300833A (ja) * 1991-03-29 1992-10-23 Green Cross Corp:The プロスタグランジンｅ１　含有脂肪乳剤充填噴霧剤
TW367324B (en) * 1995-08-16 1999-08-21 Ono Pharmaceutical Co Prostaglandin derivatives
JP2802912B2 (ja) * 1995-08-16 1998-09-24 小野薬品工業株式会社 プロスタグランジンｅ１エステル、それらを含有するリポソーム製剤、およびそれらを含有する医薬
JPH09124593A (ja) * 1995-08-25 1997-05-13 Ono Pharmaceut Co Ltd プロスタグランジンｅ１エステル、それらを含有するリポソーム製剤、およびそれらを含有する医薬
KR100227541B1 (ko) * 1995-08-25 1999-11-01 우에노 도시오 프로스타글란딘 유도체
WO2003092617A2 (en) * 2002-05-03 2003-11-13 Combinatorx, Incorporated Combinations for the treatment of inflammatory skin disorders
US7737182B2 (en) * 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
JP2005139194A (ja) * 2002-08-09 2005-06-02 Taisho Pharmaceut Co Ltd 止痒剤
US7547715B2 (en) * 2002-10-10 2009-06-16 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production accelerator
WO2006093348A2 (en) * 2005-03-04 2006-09-08 Sucampo Ag Method and composition for treating peripheral vascular diseases
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
CN101180096B (zh) * 2005-03-21 2015-04-22 苏坎波公司 用于治疗粘膜疾病的方法和组合物
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途

Also Published As

Publication number Publication date
BRPI1011658A2 (pt) 2018-03-06
ZA201109532B (en) 2012-09-26
MX2011012595A (es) 2011-12-16
JP2012528077A (ja) 2012-11-12
RU2011153196A (ru) 2013-07-10
KR20120031954A (ko) 2012-04-04
NZ596555A (en) 2014-01-31
EP2435049A1 (en) 2012-04-04
TW201102070A (en) 2011-01-16
IL216218A0 (en) 2012-01-31
CN102448463A (zh) 2012-05-09
CA2761250A1 (en) 2010-12-02
WO2010137731A1 (en) 2010-12-02
AU2010253720A1 (en) 2011-12-08
US20100305203A1 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
ES2421262T3 (es) Composición para el cuidado personal y cosmética que contiene tetrapéptidos con las unidades CX1X2G, PX1X2P o PX1X2K
BR112015020196A2 (pt) uma composição tópica para clareamento e métodos de uso da mesma
ES2129013B1 (es) Utilizacion de la vitamina c o de sus derivados o analogos para estimular la sintesis de la elastina cutanea.
DOP2022000121A (es) Derivados de 3-(5-metoxi-1-oxoisoindolin-2-il)piperidin-2,6-diona y usos de los mismos
PE20080844A1 (es) Uso de moduladores lxr para la prevencion y tratamiento del envejecimiento de la piel
UY27878A1 (es) Derivados de indolinfenilsulfonamida
BR112014029766A2 (pt) composições contendo álcoois graxos, tensoativos catiônicos e n-acil-n-metilglucaminas
BRPI0910874B8 (pt) formulação tópica para uso no tratamento tópico de uma condição da pele que resulta da produção de espécies reativas de oxigênio e/ou para a promoção da cicatrização de ferida tópica na pele de um indivíduo e uso da referida formulação
CO6430467A2 (es) Péptidos útiles en el tratamiento y/o cuidado de la piel y/o cabello y su uso en composiciones cosméticas o farmacéuticas
BR112014031837A2 (pt) formulações de progesterona
ECSP13012668A (es) Ácidos 1-bencilcicloalquilcarboxílicos sustituidos y su uso
UY31310A1 (es) Ácidos 6-fenilnicotínicos sustituidos y su uso
WO2008028636A1 (en) Skin care composition
BR112012015433B8 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
BR112015007102A2 (pt) composição de lipídios vegetais para a modulação de funções de matérias queratínicas, método para modulação das referidas funções e uso dos referidos lipídios vegetais
Singh et al. Wound healing activity of standardized extract of Curculigo orchioides in streptozotocin–induced diabetic mice
AR084197A1 (es) Composicion para uso topico para el tratamiento de trastornos de la piel
BRPI0507622A (pt) composto baseado em ácido hialurÈnico, sal de sódio, processo para preparar um composto ou um seu sal, composição farmacêutica, produto medicinal e dispositivo médico para uso humano ou veterinário, e, uso de composto ou de seu sal
AR076929A1 (es) Composicion farmaceutica para modular las funciones mediadas por claudina. uso de un derivado de acido graso
BRPI0520753B8 (pt) artigo absorvente
Kim et al. Chitooligomers inhibit UV-A-induced photoaging of skin by regulating TGF-β/Smad signaling cascade
PA8488701A1 (es) Composiciones obtenidas a partir de mangifera indica l
AR094035A1 (es) Estimulantes del colageno y su uso en el tratamiento de la piel
MX2013012038A (es) Combinacion de carotenoide, fitoestrogeno y vitamina c para la humectacion de la piel.
US9682025B2 (en) Combination of active agents for oral administration for improving the quality of nails

Legal Events

Date Code Title Description
FB Suspension of granting procedure